Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial of Novel Cancer Drug

Dewpoint Therapeutics has dosed the first patient in a Phase 1a/2a clinical trial of DPTX3186, a first-in-class therapy for advanced solid tumors, with an initial focus on gastric cancer. The drug is designed to modulate disease-associated biomolecular condensates—tiny, non-membrane-bound structures that organize the cellular machinery responsible for activating genes.

The scientific foundation for this therapy was established through research at Whitehead Institute led by Richard Young, a Member of Whitehead Institute and professor of biology at Massachusetts Institute of Technology. Over the past decade, Young's laboratory has helped redefine how cells regulate their genetic programs. His team demonstrated that transcription is often organized within condensates that concentrate key proteins and RNA molecules, revealing an unexpected layer of cellular organization and reshaping how scientists understand gene control in both healthy and diseased cells.

Building on this work, Young and colleagues showed that cancer-associated mutations can disrupt how condensates form or function. Such changes can alter cellular behavior in ways that promote tumor growth, pointing to condensates as potential therapeutic targets. Young co-founded Dewpoint Therapeutics to translate these fundamental discoveries into novel therapies. The ongoing trial represents an early clinical evaluation of an approach rooted in discoveries first made at Whitehead Institute.

At Whitehead, Young's laboratory continues to lead research into the molecular principles governing condensate formation, gene regulation in healthy and diseased cells, and the broader implications of condensate biology across cancer and other diseases.